Annovis Bio Inc
$ 1.78
1.14%
16 Apr - close price
- Market Cap 51,514,000 USD
- Current Price $ 1.78
- High / Low $ 1.80 / 1.70
- Stock P/E N/A
- Book Value 0.62
- EPS -1.40
- Next Earning Report 2026-05-12
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -1.06 %
- ROE -2.21 %
- 52 Week High 5.50
- 52 Week Low 1.21
About
Annovis Bio, Inc., a clinical-stage drug platform company, develops drugs to treat neurodegeneration. The company is headquartered in Berwyn, Pennsylvania.
Analyst Target Price
$12.50
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-23 | 2025-11-05 | 2025-08-12 | 2025-05-08 | 2025-03-27 | 2024-11-06 | 2024-08-14 | 2024-05-10 | 2024-03-29 | 2023-11-08 | 2023-08-14 | 2023-05-10 |
| Reported EPS | -0.39 | -0.37 | -0.32 | -0.32 | -0.43 | -0.97 | -0.32 | -0.72 | -2.24 | -1.63 | -1.07 | -1.19 |
| Estimated EPS | -0.31 | -0.305 | -0.4031 | -0.8 | -0.2 | -0.53 | -0.63 | -0.8 | -1.3 | -1.09 | -1.14 | -0.33 |
| Surprise | -0.08 | -0.065 | 0.0831 | 0.48 | -0.23 | -0.44 | 0.31 | 0.08 | -0.94 | -0.54 | 0.07 | -0.86 |
| Surprise Percentage | -25.8065% | -21.3115% | 20.6152% | 60% | -115% | -83.0189% | 49.2063% | 10% | -72.3077% | -49.5413% | 6.1404% | -260.6061% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-05-12 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: ANVS
2026-04-15 00:39:04
Canaccord Genuity has maintained its price target for Annovis Bio (NYSE: ANVS) at $17.00 per share. This indicates the firm's continued assessment of the company's valuation.
2026-04-13 12:39:17
Annovis Bio, Inc., a Malvern-based biotech company, has successfully closed a $10 million public offering. This funding, combined with existing cash and an investment from its chairman, will extend its cash runway through Q2 2027, primarily to advance buntanetap, an oral therapy for Alzheimer's and Parkinson's diseases. The company aims to complete a Phase 3 Alzheimer's trial and submit a New Drug Application to the FDA.
2026-04-10 14:38:00
Annovis Bio (NYSE:ANVS) has successfully raised $10 million through an underwritten public offering to fund its Alzheimer's drug trial, despite a recent 29% decline in its share price. These funds, combined with existing cash, are expected to extend the company's financial runway through the second quarter of 2027, covering operations until symptomatic data readout from its Phase 3 Alzheimer’s trial and an anticipated FDA New Drug Application submission. The company's investigational drug, buntanetap, which is also being tested in Parkinson's patients, aims to inhibit neurotoxic proteins.
2026-04-10 13:10:56
Annovis Bio Inc. successfully closed an underwritten public offering, raising approximately $10 million to fund its Phase 3 Alzheimer's disease trial and an anticipated New Drug Application submission. This financing, combined with existing cash, extends the company's cash runway through Q2 2027. Despite a recent stock decline, InvestingPro analysis indicates the shares are undervalued, and the company is also pursuing an open-label extension study for Parkinson's disease and has secured new patents.
2026-04-10 12:39:33
Annovis Bio Inc. announced the closing of a $10 million public offering, which, combined with existing cash and a $1.5 million investment, extends its cash runway through Q2 2027. This funding fully finances the company's operations until the symptomatic data readout of its Phase 3 Alzheimer's disease trial and the subsequent New Drug Application submission for buntanetap. The company is also advancing an open-label extension study for Parkinson's disease and expects the 6-month data readout from its AD trial in Q1 2027.
2026-04-10 12:10:56
Annovis Bio, Inc. has closed a $10 million underwritten public offering, which, combined with existing cash and a $1.5 million investment, extends its cash runway through Q2 2027. This financing will fund operations through a key symptomatic data readout of its Phase 3 Alzheimer's disease trial and the anticipated New Drug Application (NDA) submission for buntanetap. The company is actively enrolling patients for both its Phase 3 AD trial and an open-label study for Parkinson's disease, with preparations for the AD NDA submission already underway.
